December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.37 +0.21 (+0.23%)
Streaming Delayed Price Updated: 10:39 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Market Monitor News June 03 (Cleveland-Cliffs, Blueprint Medicines UP - First Solar DOWN) ↗
Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses 
Via Chartmill
News headline image
Why BioNTech Stock Soared Today ↗
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
News headline image
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug ↗
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion. 
Via Benzinga
News headline image
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug ↗
BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
Via Stocktwits
Topics Government
News headline image
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
News headline image
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From BioNTech SE
Via GlobeNewswire
News headline image
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
News headline image
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
News headline image
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. ↗
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
News headline image
What's Going On With Vaccine Stocks Today? ↗
Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week. 
Via Benzinga
News headline image
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped. ↗
The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
Via Investor's Business Daily
Topics Bankruptcy Government
News headline image
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
News headline image
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny ↗
The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
Via Benzinga
News headline image
Where BioNTech Stands With Analysts ↗
 
Via Benzinga
News headline image
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
News headline image
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN) ↗
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
News headline image
Why BioNTech Stock Got Trounced on Tuesday ↗
Via The Motley Fool
News headline image
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion ↗
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
News headline image
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
From BioNTech SE
Via GlobeNewswire
News headline image
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks. ↗
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight. 
Via The Motley Fool
Topics Bonds World Trade
News headline image
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline ↗
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
News headline image
Why Is Summit Therapeutics Stock Trading Higher On Monday? ↗
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
News headline image
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today ↗
Via The Motley Fool
News headline image
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
From BioNTech SE
Via GlobeNewswire
News headline image
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps ↗
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
News headline image
BioNTech Surges On Summit's Coattails. But Can They Take On Merck? ↗
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
Via Investor's Business Daily
News headline image
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.